The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Several key players are shaping the global pruritus therapeutics market. Companies such as Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, and Teva Pharmaceutical ...

Biopharma Technology Co. Ltd. has led to the identification of Mas-related G-protein coupled receptor member X4 (MRGPRX4; SNSR5; SNSR6) antagonists reported to be useful for the treatment of anemia, ...

A pruritus-free day was defined as the absence ... prior to unblinding with the WHO-ART dictionary. All resources with URTICARIA in their preferred term were selected. All medical resources ...

Opens in a new tab or window BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled ...

About 30% of patients who have skin disorders are reported to have psychiatric disorders and psychosocial impairments (Kessler et al., 2005). The prevalence of psychological disorders among ...

23%; p=0.005) Complete response (urticaria activity score=0 ... by type-2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin and bullous ...